Form 4: Ideaya Biosciences Executive Acquires Stock Options

Michael Anthony White, Chief Scientific Officer of Ideaya Biosciences, acquired stock options for 140,000 shares on March 1, 2024.

Summary

• Michael Anthony White, the Chief Scientific Officer of Ideaya Biosciences, acquired stock options on March 1, 2024.
• The options grant him the right to buy 140,000 shares of common stock at an exercise price of $46.22 per share.
• The options vest over a four-year period, starting with 25% vesting on the first anniversary of January 1, 2024, and the remainder vesting monthly thereafter.
• The options expire on February 28, 2034.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard executive compensation practice. The grant itself doesn't indicate positive or negative performance, but rather aligns the executive's interests with the company's stock performance.

Positives

• The acquisition of stock options by a key executive could signal confidence in the company's future prospects.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning executive interests with shareholder value.

Stakeholder Impact

• The stock option grant aligns the executive's interests with those of the shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates